Drug Trial Radar · NCT07560449
QLS4131 Combination Therapy in Malignant Plasma Cell Neoplasms
Last checked: Nov 19, 2026Latest source record: May 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
162
Planned (sponsor's estimate)
Start
Jun 2026
Primary completion
Jun 2028
Study completion Jun 2030
Sponsor
- Lead sponsor
- Qilu Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- May 1, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to compare the efficacy of QLS4131(SC) in combination with QL2109, with or without pomalidomide or lenalidomide, and QLS4131 (SC) in combination with QL2109, and QLS4131 (SC) in combination with Pomalidomide, and QLS4131(SC) in combination with QL2109 and Lenalidomide.
Conditions
- Malignant Plasma Cell Neoplasms
Interventions
QLS4131Drug
QLS4131 will be administered subcutaneously.
QL2109Drug
QL2109 will be administered subcutaneously.
PomalidomideDrug
Pomalidomide will be self-administered as a single dose orally.
LenalidomideDrug
Lenalidomide will be self-administered as a single dose orally.
DexamethasoneDrug
Dexamethasone will be administered orally or intravenously.
Primary outcomes
What the sponsor says the trial is designed to measure.
- DLTTime frame: From time of the first dose of QLS4131 to end of DLT period (28 days)
- MTDTime frame: Up to 2 years
- ORR (Partial Response [PR] or Better)Time frame: Up to 2 years
- Overall Minimal Residual Disease (MRD)Time frame: Up to 2 years
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.